Loading
Lorigerlimab is an experimental bispecific antibody from MacroGenics in phase 2 trials for ovarian cancer, vulvar cancer and cervical cancer, aimed at PD-1 and CTLA-4.
Lorigerlimab (MGD019) is a bispecific antibody developed by MacroGenics. Its targets are PD-1 and CTLA-4 (the sponsor names PD-1 x CTLA-4). The sponsor states: A DART (Dual Affinity Re-Targeting) bispecific protein that simultaneously engages the PD-1 and CTLA-4 checkpoint pathways to enhance anti-tumour immune responses. ClinicalTrials.gov describes the intervention as: Bispecific DART protein binding PD-1 and CTLA-4. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, vulvar cancer, cervical cancer and endometrial cancer. The largest, NCT06730347, plans to enrol 80 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of Lorigerlimab binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Lorigerlimab" OR ABSTRACT:"Lorigerlimab" OR TITLE:"MGD019" OR ABSTRACT:"MGD019") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lorigerlimab, not a curated reading list.
Shares MacroGenics and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Ovarian cancer and the tag pipeline.
Shares MacroGenics and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Cervical cancer, Ovarian cancer and the tag pipeline.